Alignment Healthcare, Inc. (NASDAQ:ALHC) President Dawn Christine Maroney Sells 11,152 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) President Dawn Christine Maroney sold 11,152 shares of the business’s stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $17.89, for a total value of $199,509.28. Following the sale, the president now owns 2,362,899 shares in the company, valued at approximately $42,272,263.11. The trade was a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Dawn Christine Maroney also recently made the following trade(s):

• On Wednesday, March 19th, Dawn Christine Maroney sold 16,535 shares of Alignment Healthcare stock. The shares were sold at an average price of $16.40, for a total value of $271,174.00.
• On Monday, March 17th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $15.99, for a total transaction of $479,700.00.
• On Wednesday, March 12th, Dawn Christine Maroney sold 27,243 shares of Alignment Healthcare stock. The stock was sold at an average price of $15.43, for a total transaction of $420,359.49.
• On Thursday, March 6th, Dawn Christine Maroney sold 278,917 shares of Alignment Healthcare stock. The shares were sold at an average price of $15.53, for a total value of $4,331,581.01.
• On Tuesday, February 18th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $13.72, for a total transaction of $411,600.00.
• On Wednesday, January 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $13.61, for a total transaction of $408,300.00.

Alignment Healthcare Stock Performance

Shares of ALHC stock opened at $18.30 on Friday. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of -23.77 and a beta of 1.49. The stock has a fifty day moving average of $15.28 and a 200 day moving average of $12.97. Alignment Healthcare, Inc. has a 52 week low of $4.46 and a 52 week high of $18.44. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 1.82.

Institutional Investors Weigh In On Alignment Healthcare

Institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Alignment Healthcare by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,963 shares of the company’s stock valued at $641,000 after buying an additional 2,154 shares during the period. Rhumbline Advisers grew its holdings in shares of Alignment Healthcare by 2.2% during the 4th quarter. Rhumbline Advisers now owns 135,704 shares of the company’s stock worth $1,527,000 after acquiring an additional 2,937 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Alignment Healthcare by 5.6% during the 4th quarter. MetLife Investment Management LLC now owns 61,344 shares of the company’s stock worth $690,000 after acquiring an additional 3,256 shares during the period. Alliancebernstein L.P. raised its position in shares of Alignment Healthcare by 2.8% in the 4th quarter. Alliancebernstein L.P. now owns 119,440 shares of the company’s stock worth $1,344,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of Alignment Healthcare by 15.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 34,497 shares of the company’s stock valued at $388,000 after purchasing an additional 4,497 shares during the period. 86.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. William Blair reissued an “outperform” rating on shares of Alignment Healthcare in a research note on Friday, February 28th. Barclays raised their price objective on Alignment Healthcare from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Friday, February 28th. JPMorgan Chase & Co. increased their price target on shares of Alignment Healthcare from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Thursday, March 6th. Stephens restated an “overweight” rating and issued a $17.00 price objective on shares of Alignment Healthcare in a report on Monday, February 24th. Finally, Stifel Nicolaus increased their target price on shares of Alignment Healthcare from $16.00 to $18.00 and gave the company a “buy” rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.